We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Third FDA Advisory Panel Expert Resigns Over Aducanumab Approval
Third FDA Advisory Panel Expert Resigns Over Aducanumab Approval
A third member of the FDA’s Peripheral and Central Nervous System Advisory Committee departed from the panel this week after the agency chose to approve Biogen’s Alzheimer’s drug Aduhelm (aducanumab).